

Table of Contents

1. Introduction	1
1.1. <i>Germinal centers in normal B cells responses.....</i>	1
1.2. <i>B-cell non-Hodgkin lymphomas.....</i>	3
1.3. <i>Follicular lymphoma (FL).....</i>	4
1.3.1. FL origin, transformation and molecular alterations.....	4
1.3.2. The tumor microenvironment in FL.....	5
1.3.3. FL diagnosis and clinical prognosis.....	6
1.3.4. FL therapeutic approaches.....	7
1.4. <i>Diffuse large B-cell lymphoma (DLBCL).....</i>	8
1.4.1. DLBCL subtypes based on their Cell-of-Origin (COO).....	8
1.4.2. Germinal center B cell (GCB) DLBCL origin and molecular alterations.....	8
1.4.3. Activated B cell (ABC) DLBCL origin and molecular alterations.....	9
1.4.4. The tumor microenvironment in DLBCL.....	11
1.4.5. DLBCL diagnosis and clinical prognosis.....	12
1.4.6. DLBCL therapeutic approaches.....	12
1.5. <i>The B cell receptor (BCR) signaling pathway in normal and transformed B cells....</i>	14
1.5.1. BCR signaling transduction pathways.....	14
1.5.2. Regulation of the BCR signaling.....	17
1.5.3. BCR signaling alterations and dependencies in FL and DLBCL.....	18
1.5.4. Targeting the BCR signaling for FL and DLBCL treatment.....	19
1.5.5. The consequences of BCR ligation beyond the intracellular signaling.....	21
1.6. <i>MHCI and MHCII antigen presentation routes.....</i>	21
1.6.1. MHCII antigen presentation to CD4+ T cells.....	21
1.6.2. MHC I antigen presentation to CD8+ T cells.....	25
1.6.3. Cross-presentation.....	27
1.7. <i>Cathepsin S in antigen presentation and tumor immunity.....</i>	28
1.7.1. Cysteine cathepsin proteases.....	28
1.7.2. The multiple roles of the cysteine protease cathepsin S.....	29
2. Aim of the thesis.....	33

3. Results: Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma	35
3.1. Context and aims.....	35
3.2. Main findings	36
3.3. Conclusions and perspectives	39
4. Results: Multimodal inhibition of the BCR signaling affects DLBCL heterogeneity and evolution	43
4.1. Context and aims.....	43
4.1.1. Acquired resistance to ibrutinib	43
4.1.2. Therapeutic strategies to circumvent ibrutinib acquired resistance	44
4.1.3. Analysis of intra-tumor heterogeneity with single-cell transcriptomic approaches	46
4.2. Methods	47
4.3. Main findings	49
4.3.1. Tumor relapse in a patient-derived xenograft model of ABC DLBCL.....	49
4.3.2. Ibrutinib and masitinib acquired resistance is not driven by genomic alterations in a model of ABC DLBCL.....	51
4.3.3. Single-cell transcriptomics analysis of DLBCL heterogeneity.....	51
4.3.4. Ibrutinib and masitinib treatments change the transcriptomic landscape of ABC DLBCL at the single-cell level.....	53
4.3.5. Bulk transcriptomics analysis of ibrutinib and masitinib treated tumors confirms the trends observed at the single-cell level	62
4.4. Conclusions and perspectives	64
5. Results: Cathepsin S inhibition enhances tumor antigen heterogeneity and anti-tumor immunity	67
5.1. Context and aims.....	67
5.2. Main findings	68
5.3. Conclusions and perspectives	71
6. Concluding remarks	75
Bibliography	79

Appendix 1. Battistello E et al., Blood, 2018. Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma	91
A1.1. Article information	91
A1.2. Copyright information.....	91
Appendix 2. Dheilly E*, Battistello E* et al. Cathepsin S inhibition enhances tumor antigen heterogeneity and anti-tumor immunity	105
A2.1. Article information	105
Curriculum Vitae	163